In an era of health reform, diagnostic technologies that focus on prevention and test the viability of expensive treatment options are becoming increasingly valuable to health providers, payers, and patients. Historically, investment in this sector has not seen the vigor demonstrated with medical devices or biotech innovations. However, in today’s environment, diagnostics are becoming attractive opportunities for companies looking for collaborations or acquisitions as well as investors looking for cutting-edge technologies, all creating a robust industry on the brink of breaking through to the mainstream.
In this presentation, panelists will:
- Provide insight on the diagnostic industry on a local and national level
- Discuss key elements that are reviewed when assessing start-up opportunities
- Discuss where opportunities exist for maximizing profits
- Provide new strategies for raising funds in this dynamic marketplace
Panelist:
Ronald S. Eppen, Partner, Foley & Lardner LLP
Lucy Lu, Vice President of Business Development, Crescendo Bioscience
Natasha Paul, Ph.D., Scientific Investigator, TriLink Biotechnologies, Inc.
Jon Vance, Director, Avondale Partners, LLC
Related Insights
19 November 2024
Events
Privacy Law Issues Confronting the Cannabis and Hemp Economy
Foley Partner Aaron Tantleff joins the faculty for a California Lawyers Association (CLA) webinar aimed at providing California lawyers with an introduction to privacy law concepts and issues that intersect with commercial cannabis and hemp.
13 November 2024
Events
Florida Institute of CFOs (fiCFO) 2024 Summit
Foley Partner Aaron Tantleff is a featured speaker at the Florida Institute of CFOs (fiCFO) 2024 Summit taking place near Orlando on November 12-14, 2024, which Foley is proud to support as a Platinum Sponsor.
14 November 2024
Events
ABA Antitrust Law Section Fall Forum Debate: Anticompetitive Conduct is Best Determined by the FTC
During the Fall Forum of the American Bar Association Antitrust Law Section, Partner Diane Hazel will moderate a debate that will argue the pros and cons of whether anticompetitive conduct is best determined by the FTC.